Thrombolytic therapy for stroke: the new paradigm.
Roughly 80% of patients with acute stroke have thromboocclusive disease and may benefit from clot lysis with recombinant tissue plasminogen activator. To be effective, however, such treatment must be administered within three hours of stroke onset in carefully selected patients. Hospital protocols that mobilize an acute stroke team to minimize delays are needed nationwide.
Levine
S R
SR
University of Michigan Medical School, Detroit, USA.
D000208:Acute Disease; D000818:Animals; D002561:Cerebrovascular Disorders / Q000188:drug therapy*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D013300:Streptokinase / Q000627:therapeutic use*; D015912:Thrombolytic Therapy; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000627:therapeutic use*
D005343:Fibrinolytic Agents; D013300:Streptokinase; D010959:Tissue Plasminogen Activator